Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8113473 | 0.82 | L3MBTL1 (0.41) | ALDH1A1CYP3A4CA12CA1CA2 | |
| SCHEMBL25153458 | 0.81 | APP (0.41) | ALDH1A1CYP3A4CYP1A2CYP2D6APP | |
| SCHEMBL25060038 | 0.81 | CYP1A2 (0.47) | ALDH1A1CYP3A4CYP1A2CYP2D6APP | |
| Bromide SCHEMBL20984741 | 0.80 | L3MBTL1 (0.40) | ALDH1A1CYP3A4CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL20984940 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CYP3A4CA12CA1CA2 | |
| SCHEMBL5514195 | 0.79 | MAPT (0.44) | ALDH1A1APPHPGDL3MBTL1MAPT | |
| SCHEMBL630768 | 0.79 | CA1 (0.58) | ALDH1A1CYP3A4CA12CA1CA2 | |
| SCHEMBL21893894 | 0.79 | MPL (0.41) | GAA | |
| SCHEMBL360496 | 0.78 | CA1 (0.57) | ALDH1A1APPCA12CA1CA2 | |
| SCHEMBL29636384 | 0.78 | CA1 (0.57) | ALDH1A1APPCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462659-A | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113874079-B | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023064584-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064585-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-111039940-B | Aurora A kinase inhibitor, preparation method, pharmaceutical composition and application thereof | 北京鑫开元医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114728962-A | Plasma kallikrein inhibitors and uses thereof | 武田药品工业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113874079-A | Bridged tricyclic carbamoylpyridone compounds and pharmaceutical use thereof | 吉利德科学公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2021110009-A1 | NOVEL AURORA KINASE INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2021-06-10 | — | — | WO | disclosed |
| WO-2021008338-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2021-01-21 | — | — | WO | disclosed |
| CN-111039940-A | Aurora A kinase inhibitor, preparation method, pharmaceutical composition and application thereof | 北京鑫开元医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |